Uses
Consider potential benefits and risks of celecoxib therapy as well as alternative therapies before initiating therapy with the drug. Use lowest effective dosage and shortest duration of therapy consistent with the patient's treatment goals.
Osteoarthritis
Symptomatic treatment of osteoarthritis. Effect comparable to that of prototypical NSAIAs (naproxen).
Lower incidence of endoscopically confirmed GI ulcer and serious adverse GI effects than prototypical NSAIAs.
Rheumatoid Arthritis in Adults
Symptomatic treatment of rheumatoid arthritis in adults. Effect comparable to that of prototypical NSAIAs (naproxen, diclofenac).
Lower incidence of endoscopically confirmed GI ulcer and serious adverse GI effects than prototypical NSAIAs.
Juvenile Arthritis
Symptomatic management of pauciarticular course, polyarticular course, or systemic onset juvenile rheumatoid arthritis in children ≥2 years of age. Effect comparable to that of naproxen.
Ankylosing Spondylitis
Management of the signs and symptoms of ankylosing spondylitis.
Colorectal Polyps
Reduction of the number of adenomatous colorectal polyps (colorectal adenomas) in adults with familial adenomatous polyposis (FAP); used as an adjunct to usual care. Not known whether celecoxib reduces the risk of colorectal, duodenal, or other FAP-related cancers.
Has been investigated for the prevention of colorectal adenomas in patients without a history of FAP†. Use of celecoxib reduces the risk of recurrent colorectal adenomas; not known whether celecoxib reduces the risk of colorectal cancer. Routine use not recommended because of the potential for serious cardiovascular events.
Pain
Management of acute pain, including postoperative (e.g., dental, orthopedic) pain, in adults.
Dysmenorrhea
Symptomatic management of primary dysmenorrhea in adults.
Cardiovascular Risk Reduction
Not a substitute for aspirin in the prevention of adverse cardiovascular events (MI). (See Cardiovascular Effects under Cautions.)
Dosage and Administration
General
- Consider potential benefits and risks of celecoxib therapy as well as alternative therapies before initiating therapy with the drug.
Administration
Oral Administration
Administer orally once or twice daily for osteoarthritis or ankylosing spondylitis; administer twice daily for rheumatoid arthritis, juvenile arthritis, colorectal polyps, pain, or dysmenorrhea.
Administer dosages up to 200 mg twice daily without regard to meals; administer higher dosages (400 mg twice daily) with food.
For patients who have difficulty swallowing capsules, the capsule may be opened and the contents sprinkled onto a level teaspoonful of applesauce at room temperature or cooler, and the mixture swallowed immediately with water.
Dosage
To minimize the potential risk of adverse cardiovascular and/or GI events, use lowest effective dosage and shortest duration of therapy consistent with the patient's treatment goals.
Attempt to titrate to the lowest effective dosage in adults with arthritis.
Pediatric Patients
Juvenile Arthritis
Oral
Children ≥2 years of age weighing 10–25 kg: 50 mg twice daily.
Children ≥2 years of age weighing >25 kg: 100 mg twice daily.
Adults
Osteoarthritis
Oral
200 mg daily as a single dose or in 2 equally divided doses.
No additional benefit from dosages >200 mg daily.
Rheumatoid Arthritis in Adults
Oral
100–200 mg twice daily.
No additional benefit from higher dosages (400 mg twice daily).
Ankylosing Spondylitis
Oral
Initially, 200 mg daily as a single dose or in 2 equally divided doses. If no response observed after 6 weeks, increase to 400 mg daily. If no response observed after 400 mg daily for 6 weeks, response is unlikely; consider alternative therapies.
Colorectal Polyps
Oral
400 mg twice daily.
Pain
Oral
400 mg initially as a single dose, followed by an additional dose of 200 mg, if necessary, on the first day. For continued relief, 200 mg twice daily as needed.
Dysmenorrhea
Oral
400 mg initially as a single dose, followed by an additional dose of 200 mg, if necessary, on the first day. For continued relief, 200 mg twice daily as needed.
Special Populations
Dosage in Hepatic Impairment
Reduce dosage by 50% in patients with moderate hepatic impairment; not recommended in patients with severe impairment.
Geriatric Patients
Dosage adjustment based solely on age is not necessary; initiate at lowest recommended dosage in geriatric patients weighing <50 kg.
Print
Email
Save
FDA Alerts
Media Gallery
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
